Selected article for: "recovery rate and standard addition"
Author: Budhathoki, Pravash; Shrestha, Dhan Bahadur; Rawal, Era; Khadka, Sitaram
Title: Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis
  • Cord-id: c8qjloc2
  • Document date: 2020_10_19
    • ID: c8qjloc2
    Snippet: Due to a lack of definitive treatment, many drugs were repurposed for Coronavirus disease (COVID-19) treatment; among them, corticosteroid is one. However, its benefit or harm while treating COVID-19 is not fully studied. Thus, we conducted this meta-analysis to assess the rationality on the use of corticosteroids in COVID-19. Pubmed, Medline, Clinicaltrials.gov, Cochrane library, and Preprint publisher were searched. In the qualitative syntheses, 41, and quantitative studies, 40, were included
    Document: Due to a lack of definitive treatment, many drugs were repurposed for Coronavirus disease (COVID-19) treatment; among them, corticosteroid is one. However, its benefit or harm while treating COVID-19 is not fully studied. Thus, we conducted this meta-analysis to assess the rationality on the use of corticosteroids in COVID-19. Pubmed, Medline, Clinicaltrials.gov, Cochrane library, and Preprint publisher were searched. In the qualitative syntheses, 41, and quantitative studies, 40, were included using PRISMA guidelines. Assessment of heterogeneity was done using the I-squared (I(2)) test and random/fixed effect analysis was done to determine the odds/risk ratio. We found severely ill COVID-19 patients almost 5 (OR 4.78, 2.76–8.26) times higher odds of getting corticosteroids during their treatment. Similarly, the odds for corticosteroids in addition to standard of care (SOC) were approximately 4 (OR 4.09, 1.89–8.84) times higher among intensive care unit (ICU) patients than non-ICU ones. A higher mortality risk with the corticosteroid-receiving group compared with the SOC alone (RR 2.01, 1.12–3.63) was observed. Neither increased discharge rate (RR 0.79, 0.63–0.99) nor recovery/improvement rate was shown among the corticosteroid-receiving group (OR 0.24, 0.13–0.43). Approximately, the overall 4-day longer hospital stay was found among the treatment groups (MD 4.19, 2.57–5.81). For the negative conversion of reverse transcription–polymerase chain reaction (RT-PCR), approximately a 3-day (MD 2.42, 1.31–3.53) delay was observed with corticosteroid treatment cases. Our study concludes that more severe and critically ill patients tend to get corticosteroids, and the mortality risk increases with the use of corticosteroids. With the use of corticosteroids, delayed recovery and a longer hospital stay were observed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s42399-020-00515-6) contains supplementary material, which is available to authorized users.

    Search related documents:
    Co phrase search for related documents
    • abbreviations ards and acute respiratory distress syndrome: 1, 2, 3
    • abbreviations ards and acute respiratory distress syndrome abbreviations ards: 1, 2, 3
    • abbreviations ards and acute respiratory syndrome coronavirus: 1, 2
    • abbreviations ards and acute sars cov respiratory syndrome coronavirus: 1
    • abstract title and acute ards respiratory distress syndrome: 1
    • abstract title and acute respiratory distress syndrome: 1
    • abstract title and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • abstract title and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abstract title and additional file: 1
    • active phase and acute ards respiratory distress syndrome: 1
    • active phase and acute respiratory distress syndrome: 1
    • active phase and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • active phase and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • active phase and additional file: 1
    • acute ards respiratory distress syndrome and add benefit: 1
    • acute ards respiratory distress syndrome and addition corticosteroids: 1, 2
    • acute ards respiratory distress syndrome and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory distress syndrome and add benefit: 1
    • acute respiratory distress syndrome and addition corticosteroids: 1, 2, 3